Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1986 1
1987 2
1988 15
1989 40
1990 32
1991 23
1992 34
1993 34
1994 37
1995 31
1996 39
1997 30
1998 34
1999 25
2000 36
2001 31
2002 49
2003 34
2004 38
2005 45
2006 50
2007 54
2008 58
2009 72
2010 64
2011 88
2012 79
2013 75
2014 76
2015 92
2016 93
2017 104
2018 94
2019 114
2020 124
2021 121
2022 139
2023 107
2024 53

Text availability

Article attribute

Article type

Publication date

Search Results

2,025 results

Results by year

Filters applied: . Clear all
Page 1
Treatment and biology of pediatric acute lymphoblastic leukemia.
Kato M, Manabe A. Kato M, et al. Pediatr Int. 2018 Jan;60(1):4-12. doi: 10.1111/ped.13457. Pediatr Int. 2018. PMID: 29143423 Review.
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. ...Treatment for pediatric ALL typically consists of induction therapy with steroids, vincristine, and asparaginase with or without anthracycline, followed by multi-agent consolidatio …
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. ...Treatment for pediatric ALL typically consists …
Adult Acute Lymphoblastic Leukemia: Treatment and Management Updates.
Gregory S. Gregory S. Semin Oncol Nurs. 2019 Dec;35(6):150951. doi: 10.1016/j.soncn.2019.150951. Epub 2019 Nov 20. Semin Oncol Nurs. 2019. PMID: 31759820 Review.
OBJECTIVE: To present an overview of novel therapies for the treatment of adult acute lymphoblastic leukemia and to discuss nursing implications for these new therapies. DATA SOURCES: Published manuscripts, Web sites, and pharmaceutical package inserts …
OBJECTIVE: To present an overview of novel therapies for the treatment of adult acute lymphoblastic leukemia and to dis …
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Abou Dalle I, Jabbour E, Short NJ, Ravandi F. Abou Dalle I, et al. Curr Treat Options Oncol. 2019 Jan 24;20(1):4. doi: 10.1007/s11864-019-0603-z. Curr Treat Options Oncol. 2019. PMID: 30675645 Free PMC article. Review.
With the introduction of tyrosine kinase inhibitors (TKIs) in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), the prognosis of patients has improved dramatically. ...Clinicians should be aware of possible fatal cardiovascul …
With the introduction of tyrosine kinase inhibitors (TKIs) in the management of Philadelphia chromosome-positive acute lymphoblastic …
Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults.
Temple WC, Mueller S, Hermiston ML, Burkhardt B. Temple WC, et al. Best Pract Res Clin Haematol. 2023 Mar;36(1):101449. doi: 10.1016/j.beha.2023.101449. Epub 2023 Feb 16. Best Pract Res Clin Haematol. 2023. PMID: 36907639 Free article. Review.
Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin Lymphoma (NHL) in children, adolescents, and young adults (CAYA), accounting for 25-35% of all cases. T-lymphoblastic lymphoma (T-LBL) comprises 70-80% of cases, while …
Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin Lymphoma (NHL) in children, adolescents, and …
Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia.
Harvey RC, Tasian SK. Harvey RC, et al. Blood Adv. 2020 Jan 14;4(1):218-228. doi: 10.1182/bloodadvances.2019000163. Blood Adv. 2020. PMID: 31935290 Free PMC article. Review.
Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) accounts for 15% to 30% of B-cell acute lymphoblastic leukemia in older children, adolescents, and adults and is associated with high rates of conventional tre …
Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) accounts for 15% to 30% of B-cell …
Mixed Phenotype Acute Leukemia: Current Approaches to Diagnosis and Treatment.
Alexander TB, Orgel E. Alexander TB, et al. Curr Oncol Rep. 2021 Feb 5;23(2):22. doi: 10.1007/s11912-020-01010-w. Curr Oncol Rep. 2021. PMID: 33544265 Review.
PURPOSE OF REVIEW: Mixed phenotype acute leukemia (MPAL) is a rare subtype of acute leukemia with features of both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). ...Differences in prognosis for adult and children with MPAL …
PURPOSE OF REVIEW: Mixed phenotype acute leukemia (MPAL) is a rare subtype of acute leukemia with features of both acute ly …
Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.
Qayed M, McGuirk JP, Myers GD, Parameswaran V, Waller EK, Holman P, Rodrigues M, Clough LF, Willert J. Qayed M, et al. Cytotherapy. 2022 Sep;24(9):869-878. doi: 10.1016/j.jcyt.2022.05.003. Epub 2022 Jun 17. Cytotherapy. 2022. PMID: 35718701 Free article. Review.
Tisagenlecleucel is a US Food and Drug Administration-approved CD19-directed CAR T-cell therapy for patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia and r/r diffuse large B-cell lymphoma. ...CAR T-cell …
Tisagenlecleucel is a US Food and Drug Administration-approved CD19-directed CAR T-cell therapy for patients with relapsed/ref …
Recent advances in the treatment of acute lymphoblastic leukemia.
Rafei H, Kantarjian HM, Jabbour EJ. Rafei H, et al. Leuk Lymphoma. 2019 Nov;60(11):2606-2621. doi: 10.1080/10428194.2019.1605071. Epub 2019 May 16. Leuk Lymphoma. 2019. PMID: 31092071 Review.
Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with a bimodal distribution. ...Tyrosine kinase inhibitors (TKI) targeting BCR-ABL1 tyrosine kinase, monoclonal antibodies targeting cell surface antigens (CD19, CD20, and CD22), bispecific antibod …
Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with a bimodal distribution. ...Tyrosine kinase inhibitors (TKI) …
Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era.
Badar T, Alkhateeb H, Aljurf M, Kharfan-Dabaja MA. Badar T, et al. Curr Res Transl Med. 2023 Apr-Jun;71(2):103392. doi: 10.1016/j.retram.2023.103392. Epub 2023 Apr 23. Curr Res Transl Med. 2023. PMID: 37121211 Review.
Before the advent of tyrosine kinase inhibitors (TKI) the outcome of Philadelphia chromosome positive (Ph(+)) acute lymphoblastic leukemia (ALL) was dismal. The TKI combination with induction regimens has greatly improved the long-term outcome of Ph(+) ALL, specific …
Before the advent of tyrosine kinase inhibitors (TKI) the outcome of Philadelphia chromosome positive (Ph(+)) acute lymphoblastic …
Multiparameter flow cytometry in the diagnosis and management of acute leukemia.
Peters JM, Ansari MQ. Peters JM, et al. Arch Pathol Lab Med. 2011 Jan;135(1):44-54. doi: 10.5858/2010-0387-RAR.1. Arch Pathol Lab Med. 2011. PMID: 21204710 Free article. Review.
In addition, detection of specific antigens may have prognostic or therapeutic implications even within a single acute leukemia subtype. After initial diagnosis, a leukemia's immunophenotypic fingerprint provides a useful reference to monitor response to t …
In addition, detection of specific antigens may have prognostic or therapeutic implications even within a single acute leukemia …
2,025 results